Positron Emission Tomography with Fluoro-2-deoxy-D-glucose (FDG-PET) in the Staging of Post Transplant Lymphoproliferative Disorder in Lung Transplant Recipients

Edith M. Marom*, H. Page McAdams, Kelly J. Butnor, R. Edward Coleman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Posttransplantation lymphoproliferative disorder (PTLD) is a histologic heterogeneous disease that complicates 4 to 8% of lung transplant recipients. Disease extent is an important prognostic factor and may affect therapy. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) has proven useful for staging high-grade lymphomas but is less accurate for staging low-grade and extranodal lymphoma. This study examined our initial experience using FDG-PET imaging to stage lung transplant recipients with posttransplantation lymphoproliferative disorder. FDG can show foci of uptake, particularly in extrathoracic sites, not seen by conventional imaging, which allows more accurate staging of disease thereby yielding useful prognostic information and guiding therapy.

Original languageEnglish
Pages (from-to)74-78
Number of pages5
JournalJournal of Thoracic Imaging
Volume19
Issue number2
DOIs
StatePublished - Apr 2004
Externally publishedYes

Keywords

  • FDG-PET
  • Lung transplantation
  • Post-transplant lymphoproliferative disorder

Fingerprint

Dive into the research topics of 'Positron Emission Tomography with Fluoro-2-deoxy-D-glucose (FDG-PET) in the Staging of Post Transplant Lymphoproliferative Disorder in Lung Transplant Recipients'. Together they form a unique fingerprint.

Cite this